
    
      This study is a Phase 3, multicenter, open-label, trial to evaluate the long-term safety and
      efficacy of intermittent chronic dosing with AXS-07 in subjects with migraine attacks.
      Eligible subjects will take AXS-07 following the onset of a migraine. Subjects will be
      treated for up to 12 months.
    
  